ZUSDURI

Advertisement

cGxPJobs Banner

UroGen Submits NDA for UGN-103 Bladder Cancer Treatment

Princeton, New Jersey — August 17, 2026 UroGen Pharma Ltd. announced the submission of a New Drug Application (NDA)...

By cGxPwire Editor
August 18, 2026

Read More

UroGen Secures U.S. Patent Protection for ZUSDURI Through 2044

PRINCETON, N.J., July 15, 2026 UroGen Pharma announced that the U.S. Patent and Trademark Office (USPTO) has issued a...

By cGxPwire Editor
July 17, 2026

Read More

UroGen Reports Strong Phase 3 UGN-103 Bladder Cancer Data

PRINCETON, N.J., May 15, 2026 UroGen Pharma Ltd. announced positive six-month results from the ongoing Phase 3 UTOPIA trial,...

By cGxPwire Editor
May 16, 2026

Read More

UroGen Pharma Expands Oncology Capabilities With New Inducement Grants

PRINCETON, N.J., December 5, 2025 — UroGen Pharma Ltd. has announced the issuance of inducement restricted stock units (RSUs)...

By cGxPwire Editor
December 5, 2025

Read More

Advertisement

cGxPJobs

Directory